Cell Biology Quiz
20 questions · no time limit
0:00
CELL-CELL AND CELL-MATRIX INTERACTIONS
Question 1 of 20
No time limit
Current
Answered
Flagged
Not seen
A pharmaceutical company develops a small molecule that prevents the binding of focal adhesion kinase (FAK) to integrin cytoplasmic domains. In cancer cell migration assays, this compound reduces cell motility without affecting initial cell attachment to fibronectin substrates. What aspect of integrin signaling is most likely disrupted by this treatment?
YOUR PROGRESS
20
QUESTIONS
Ready when you are
Answer in any order. Your progress shows here as you go.
QUESTIONS
KEYBOARD
Pick an answer ABCDE
Next question ↵→
Previous ←
Flag for review F
Answers save as you go · flagged questions come back at the end